Video Experimental Relacionado
Updated: Sep 8, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.6K
Nuevos péptidos como triagonistas de GIPR/GLP-1R/GCGR para el tratamiento de la diabetes mellitus tipo 2
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
ACS medicinal chemistry letters
|August 20, 2025
Resumen
Esta solicitud de patente introduce nuevos triagonistas de péptidos dirigidos a GIPR, GLP-1R y GCGR. Estos compuestos son prometedores para la diabetes tipo 2, la obesidad y la enfermedad hepática grasa.
Área de la Ciencia:
- Química medicinal
- Farmacología
- Endocrinología
Sus antecedentes:
- La obesidad y la diabetes mellitus tipo 2 (DMT2) son desafíos importantes para la salud mundial.
- Las terapias actuales para la DM2 y la obesidad tienen limitaciones, lo que requiere nuevas estrategias de tratamiento.
- Los agonistas de los receptores dirigidos al receptor polipeptídico inhibidor gástrico (GIPR) y al receptor de péptido 1 parecido al glucagón (GLP-1R) han demostrado beneficios terapéuticos.
Objetivo del estudio:
- Para revelar una nueva clase de triagonistas peptídicos con actividad en GIPR, GLP-1R y GCGR.
- Presentar compuestos con un perfil farmacológico único para el tratamiento de enfermedades metabólicas.
- Proporcionar una base para el desarrollo de nuevas terapias para la DM2, la obesidad y la enfermedad hepática grasa no alcohólica.
Principales métodos:
- Síntesis y caracterización de los triagonistas de péptidos.
- Evaluación farmacológica in vitro e in vivo de la actividad del receptor.
- Estudios de las relaciones estructura-actividad para optimizar las propiedades de los compuestos.
Principales resultados:
- Identificación de triagonistas peptídicos que exhiben agonismo dual o triple potente y selectivo en GIPR, GLP-1R y GCGR.
- Demostración de propiedades farmacocinéticas favorables y eficacia in vivo en modelos preclínicos.
- Establecimiento de un nuevo andamio químico para el descubrimiento de fármacos metabólicos.
Conclusiones:
- Los nuevos triagonistas de péptidos representan una nueva modalidad terapéutica prometedora.
- Estos compuestos ofrecen un tratamiento potencial para la diabetes mellitus tipo 2, la obesidad y la enfermedad hepática grasa no alcohólica.
- Un mayor desarrollo de estos triagonistas podría conducir a mejores resultados en pacientes con trastornos metabólicos.
Videos de Conceptos Relacionados
01:24Glucagon-like Receptor Agonists
415
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
415
01:23Dipeptidyl Peptidase 4 Inhibitors
249
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
249
01:06Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K